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Background: Chemokines and their receptors play a role in the innate immune response as well as in the
disruption of the balance between pro-inflammatory Th17 cells and regulatory T cells (Treg), underlying the
pathogenesis of coronary vasculitis in Kawasaki disease (KD).
Results: Here we show that genetic inactivation of chemokine receptor (CCR)-2 is protective against the induction
of aortic and coronary vasculitis following injection of Candida albicans water-soluble cell wall extracts (CAWS).
Mechanistically, both T and B cells were required for the induction of vasculitis, a role that was directly modulated
by CCR2. CAWS administration promoted mobilization of CCR2-dependent inflammatory monocytes (iMo) from the
bone marrow (BM) to the periphery as well as production of IL-6. IL-6 was likely to contribute to the depletion of
Treg and expansion of Th17 cells in CAWS-injected Ccr2+/+ mice, processes that were ameliorated following the
genetic inactivation of CCR2.
Conclusion: Collectively, our findings provide novel insights into the role of CCR2 in the pathogenesis of vasculitis
as seen in KD and highlight novel therapeutic targets, specifically for individuals resistant to first-line treatments.
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Kawasaki disease (KD) is a form of vasculitis that pre-
dominantly affects infants and toddlers, and specifically
targets coronary arteries, resulting in increased risk of
myocardial ischemia, heart disease and sudden death [1].
Although most studies describe KD in Japanese children,
KD occurs in children of all ethnicities and geographic
regions [2]. In the United States, KD remains the leading
cause of acquired heart disease, affecting up to 4,000
children each year [3]. Research in KD etiology and
pathogenesis addresses major knowledge gaps. There is
a real need to identify novel therapeutic targets for KD
since 25% of patients are resistant to intravenous im-
munoglobulin infusion (IVIG), the most common and
effective treatment for KD. Moreover, the administration
of IVIG is quite expensive and used only for symptom-
atic patients [4].* Correspondence: ahuja@uthscsa.edu
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reproduction in any medium, provided the orIncreasing clinical and experimental evidence suggests
that abnormal immune responses to infectious agent(s)
are a key component of disease initiation [5,6]. The imbal-
anced immune response fueling KD is thought to encom-
pass both the innate and adaptive immunity, as suggested
by the elevation of pro-inflammatory mediators and
increased activation of lymphocytes in KD patients [6].
In this study, we used a coronary vasculitis model, based
on the injection of a water-soluble fraction of Candida
albicans (CAWS) in C57BL/6J mice (WT) [7,8]. In this
model system, we investigated the inflammatory mediators,
including chemokines and chemokine receptors, respon-
sible for orchestrating leukocyte migration and other im-
mune processes in the pathogenesis of a form of coronary
vasculitis that resembles KD [5,9]. Four lines of evidence
suggested that the CC chemokine ligand 2 (CCL2) – CCR2
axis would play a role in coronary vasculitis. First, CCR2 is
required for monocyte/macrophage migration and activa-
tion [10], a population of cells thought to promote tissue
damage in KD [6]. Second, previous reports indicated that
there is marked up-regulation of chemokine CCL2 [11]
levels during the acute phase of KD for which the receptorl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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linked to common genetic variants in the chemokine recep-
tor gene-cluster CCR3–CCR2–CCR5 [5]. Finally, diverse
experimental models implicate CCR2 in the establishment
of tolerance or development of autoimmunity [12]. More-
over increasing evidence points towards the loss of regula-
tory mechanisms (depletion of regulatory T cells, Treg),
along with amplification of T cell driven inflammation (ex-
pansion of T helper cells producing IL-17, Th17), in KD
[13,14]. Our research highlights the critical role of CCR2 in
the pathogenesis of coronary vasculitis seen in KD and
identifies this chemokine receptor as an important deter-
minant of the Treg/Th17 balance which may be critical for
disease initiation and maintenance [13,15].
Results
Ccr2−/− mice are protected against CAWS-induced
vasculitis
We observed that injection of CAWS following the
protocol described (Additional file 1) induces vasculitis
in the coronary arteries and aortic root (Figure 1A-G)
with histological changes that have been classified as
granulomatous proliferative inflammation [8]. With this
type of inflammation the normal structure of the arteries
is destroyed (the internal elastic lamina, external elastic
lamina, and the smooth muscle layer of the tunica media
are severely damaged). Indeed in agreement with previ-
ous findings, there was a prominent infiltration of
mononuclear cells, such as histiocytes, fibroblasts, etc.,
and neutrophils (Figure 1 and data not shown).
As previously described [7,8] after CAWS injection we
quantified vasculitis severity, by enumerating five anatom-
ical sites at the level of the aortic root (Figure 1A and B),
as well as measuring the inflamed aortic wall area
(Figure 1C and D). Understanding that incidence was
defined as having one or more inflamed areas, 100% of
Ccr2+/+ mice developed coronary/aortic inflammation fol-
lowing CAWS injection compared to PBS controls and
Ccr2 null mice (Figure 1E-H), had a mean of 4–5 areas
inflamed in contrast to a mean of 0.8 areas in Ccr2−/−
mice (Figure 1I), and the area of inflammation was several
folds higher (Figure 1J).
Highlighting the specificity of the protective phenotype
afforded by CCR2 inactivation, 100% of Ccr5−/− mice
exposed to CAWS developed coronary vasculitis with
the same area of inflammation seen in wild type mice
(Figure 1H and J); and exhibiting only a small reduction
in the number of affected areas (mean = 3, Figure 1I).
Decrease inflammatory infiltrate in the heart of Ccr2−/−
mice injected with CAWS
Immunohistochemistry at the level of the aortic root
revealed that CAWS-injected Ccr2−/− mice had less macro-
phages present in the vessel wall compared with CAWS-injected Ccr2+/+ mice, (Figure 2A-B and Additional file 2).
Also, compared with CAWS-injected Ccr2+/+ mice, FACS
analysis of cell suspensions arising from the affected area
(root of the aorta) revealed that CAWS-injected Ccr2−/−
mice had significantly lower proportions of CD4+ T cells
(Figure 2C), neutrophils (Figure 2D-F), inflammatory
monocytes (iMo; Figure 2G-I), and activated dendritic cells
(Figure 2J-L), (p <0.05). Paralleling the results described
above, myeloperoxidase (MPO) levels in CAWS-injected
Ccr2+/+ mice were significantly higher in serum from
CAWS-injected mice, compared to PBS-injected mice
(Additional file 3). As expected, due to the milder vasculitis
phenotype in Ccr2−/− mice, serum MPO level post-
injection in these mice was lower than in Ccr2+/+ mice
(Additional file 3).
Ccr2−/− T and B cells are partially sufficient for protection
against CAWS-induced coronary vasculitis
Supporting the contribution of adaptive immunity in
CAWS-induced vasculitis, we found that mice lacking ma-
ture T and B lymphocytes (Rag1−/−) had a lower incidence
(50%) and decreased number of affected areas compared
with WT mice (Figure 3 and data not shown). However,
Rag1−/− mice reconstituted with WT T and B cells had a
similar phenotype as the WT mice (incidence 85%,
Figure 3). But most importantly, Rag1−/− mice reconsti-
tuted with T and B cells from Ccr2−/− mice had signifi-
cantly lower incidence of CAWS-induced vasculitis (16%)
compared with WT mice (Figure 3).
Looking at the phenotype of mice only lacking mature
T cells (nude mice) we found that compared with WT
controls, nude mice had the same disease incidence and
severity after CAWS administration (data not shown).
CAWS administration in WT mice was linked to the
elicitation of antibodies against MPO, anti-CAWS IgG1,
and IgG2a (Additional file 4 A-C). Interestingly, Ccr2−/−
mice that received CAWS administration had lower
levels of potentially pathogenic anti-MPO antibodies,
compared with WT mice (Additional file 4 A). Never-
theless, bringing into question the pathogenic role of
anti-MPO and anti-CAWS antibodies, we found that
similar to the WT mice (n= 10), 100% of B cell-deficient
mice (Igh−/− mice; n= 8) developed vasculitis, after
CAWS administration (data not shown). Together, the
data in Figure 3 using Rag1−/−, nude and Igh−/−, suggest
that T and B cells work together with the innate immune
system to induce vasculitis, but neither cell type is indis-
pensable for the induction of illness. The data also sug-
gest that CCR2 modulates the role of T and B cells in
the induction of vasculitis.
Role of CCR2 in Treg depletion and Th17 expansion
To study the role of Treg (CD4+, CD25+, Foxp3+) in
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Figure 1 Ccr2−/− mice, but not Ccr5−/− mice, are resistant to coronary/aortic inflammation after CAWS administration.
(A-B) Representative diagram and histopathology of the five areas quantified for inflammation at the aortic root that included: right coronary
artery (RCA), left coronary artery (LCA), right coronary cuspid (RCC), left coronary cuspid (LCC), and non-coronary cuspid (NCC).
(C-D) Quantification of the inflamed area at the level of the root of the aorta. (E) Normal vascular structures showing the coronaries at the level
of the root of the aorta in PBS-treated Ccr2+/+ (WT) mice. (F) Coronary and aortic inflammation in Ccr2+/+ mice after a full cycle of CAWS.
(G) Decreased inflammation in Ccr2−/− mice, at the level of the root of the aorta, after CAWS administration (all pictures have a 4X magnification
and were cropped for comparison purposes). (H) Incidence of coronary/aortic inflammation between Ccr2+/+, Ccr2−/−, and Ccr5−/− mice, after
CAWS administration. (I) Number of areas affected in the coronary and aortic wall. (J) Total area inflamed (μm2) in each group of mice receiving
two cycles of CAWS. Each bar represents the mean ± SE from a representative experiment out of 3 performed with 6–8 mice per group.
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http://www.biomedcentral.com/1471-2172/13/56administration, we compared the circulating levels of
Treg in Ccr2+/+ and Ccr2−/− mice. We found that after
two cycles of CAWS, the percentage of Treg analyzed by
FACS were significantly increased in Ccr2−/− compared
to Ccr2+/+ mice (Figure 4A). Having found that Treg
numbers were elevated after CAWS administration inCcr2−/−, we decided to evaluate if these quantities
remained constant or changed between WT and Ccr2
null mice before and after disease induction. Exam-
ination of Tregs at different time points including
7 days prior to injection of CAWS, as well as before







































































































































Figure 2 Decreased inflammatory infiltrate in the hearts of Ccr2−/− mice injected with CAWS. (A) Immunohistochemical staining of
macrophages using the marker ER-HR3 in Ccr2+/+ mice and (B) quantification (pixels) of infiltration, at the level of the root of the aorta.
(C) Absolute number of T cells (CD4+). (D) Representative FACS plots of neutrophils as defined by the expression of CD11b+ and Gr-1+ in Ccr2+/+
and (E) Ccr2−/− mice, with (F) absolute number of neutrophils. (G) FACS of iMo (CD11b+, Ly6Chi, Ly6Gint) in Ccr2+/+ mice and (H) Ccr2−/− mice,
with (I) absolute number of iMo. (J) Representative plots of dendritic cells (CD11b+, CD11c+, I-Ab+) in Ccr2+/+ mice and (K) Ccr2−/− mice.
(L) Absolute number of dendritic cells. A-L represents data collected from the heart at the level of the aortic root after two cycles of CAWS. Each
bar represents the mean ± SE from a representative experiment with 6–8 mice per group.
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tion of Tregs in circulation; however, we observed a sig-
nificant increase of these cells in Ccr2−/− mice after
disease induction, and that these numbers remained ele-
vated during the course of the disease in Ccr2−/− com-
pared to WT mice (Figure 4B). Interestingly, prior to
CAWS injection, Ccr2−/− mice had a significantly lowerproportion of Treg than Ccr2+/+ mice in circulation
(Figure 4B).
Similarly, there was a higher proportion of Treg in the
spleen of Ccr2−/− mice compare to Ccr2+/+ mice 30 days
after completing two cycles of CAWS (Figure 4C). Sub-
stantiating this observation further, we found that com-


















  T and B 
cells source
*
WT (Rag1+/+) + CAWS
Rag1-/-  (T and B cell deficient) + CAWS
Rag1-/-  + WT (T and B cells) + CAWS
Rag1-/-  + Ccr2-/- (T and B cells) + CAWS
Figure 3 Contribution of T and B cells to the development of
coronary/aortic inflammation after CAWS administration.
Incidence of coronary inflammation after CAWS administration in
Rag1−/− mice receiving T and B cells from Ccr2+/+ mice or Ccr2−/−
mice. Each bar represents the mean ± SE from a representative
experiment with 6–8 mice per group.
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released higher levels of IL-10 (Figure 4D) and active
TGF-β (Figure 4E), cytokines that have been associated
with Treg. Finally, there was an induction in the propor-
tion of Treg in circulation after disease initiation, as well
as the cytokines involved in Treg proliferation/differen-
tiation, seen in Ccr2 null mice. Based on this observation
we decided to investigate if the presence of Treg in the
locally affected areas (heart/coronaries) provided the
protection seen in these animals compared to the WT.
Treg cells were not detected in the heart using flow
cytometry (CD4+CD25+Foxp3+) and RT-PCR (FoxP3)
(data not shown). These results indicate that most likely
the suppression conferred by Treg occurs distal to the
inflamed regions (e.g. spleen).
Conversely, CAWS-injected Ccr2+/+ mice had a higher
proportion of CD4+ and IL-17A+ cells (Th17) in the
spleen, compared with Ccr2−/− mice (Figure 4F). Sup-
porting the notion that an imbalance between Treg and
Th17 consequently leads to coronary vasculitis, we
found a significant negative correlation between the pro-
portion of Treg and Th17 cells in the spleen
(Figure 4G). Nevertheless, we also found a reduced Th1
and Th2 response in the spleens of CAWS- injected
Ccr2−/− mice (Additional file 5), suggesting thatincreased Treg in the spleens of Ccr2−/− mice may be
associated with broader modulation of T cell responses.
Additionally, to determine the suppressor activity of
Treg in the context of CCR2, functional assays were
used in Ccr2+/+ and Ccr2−/− mice. Treg from PBS-
injected groups developed a clear suppressor activity
characterized by decreased proliferation of responder
CD4+ cells with different ratios. Interestingly, a stronger
suppressor activity was found in Ccr2 intact mice under
different ratios of responder CD4+ cells compared with
the Ccr2 null mice (data not shown). Using the first
cycle of CAWS for development of coronary vasculitis
(19 days after CAWS administration), the same outcome
was seen using a 1:1 proportion (responder:Treg), no
differences were found at 1:2, and the opposite was
found at 1:5 (data not shown). Finally, to compare the
functional effect of Ccr2 on the ability of Treg to sup-
press proliferation, Treg from Ccr2+/+ or Ccr2−/− mice
were cultured with responder CD4+ T cells of the oppos-
ite genotype. Notably, Treg from Ccr2 null mice showed
a significant suppressor activity against Ccr2+/+
responder T cells compared with regulatory T cells from
Ccr2+/+ with Ccr2−/− responder cells at different ratios
(Figure 4H), indicating that absence of Ccr2 can further
enhance the suppressive capabilities of Treg.
Lastly, we evaluated a pharmacological approach to
block CCR2 and its impact on the proportion of Treg.
For this, propagermanium (PPGM) was used as a CCR2
blocker as has been demonstrated by Yokochi et al. [16]
and others [17-20]. Remarkably, oral administration of
PPGM significantly increased the percentage of Treg in
circulation in Ccr2 intact mice, compared to animals
that did not receive treatment, following a trend similar
to the one observed in Ccr2 null mice (Figure 4I) and
confirming our previous findings.
Decreased immune response in CAWS-injected Ccr2−/−
mice
In silico “pathways analysis” correlating CCR2, Th17 (IL-
17A) and Tregs pointed at IL-6 as a molecular candidate
linking the effect(s) of CCL2-CCR2-dependent signals
on the Treg/Th17 balance (Figure 5A). Therefore, we
measured serum levels of IL-6 in PBS- or CAWS-
injected mice on days 10 and 30 after the first cycle of
CAWS. The data revealed a systemic rise in the levels of
IL-6 in Ccr2+/+ after CAWS injection that was amelio-
rated in Ccr2−/− mice (Figure 5B). In agreement with the
serum data, culture supernatants of splenocytes activated
with anti-CD3/CD28 from CAWS-injected mice con-
tained higher levels of IL-6 in Ccr2+/+ compared with
Ccr2−/− mice (Figure 5C). Moreover, highlighting pos-
sible links between reduced IL-6 production and lower
proportion of Th17 cells in the spleen, we found a sig-
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Figure 4 Increased Treg and reduced Th17 cells in Ccr2−/− mice that received CAWS. (A) Representative FACS of circulating Tregs gated on
CD4+ cells (CD4+, CD25+, Foxp3+) from Ccr2+/+ mice (upper panel) and Ccr2−/− mice (lower panel), after two cycles of CAWS. (B) Percentage of
Treg in circulation in Ccr2+/+ mice and Ccr2−/− mice, 1 week prior (day −7), day 19 and day 97 post-CAWS administration. (C) Quantification of
Tregs in freshly isolated splenocytes derived from Ccr2+/+ mice and Ccr2−/− mice that received a full cycle of CAWS. (D-E) Levels of IL-10 and
TGF-β in cell culture supernatants of splenocytes stimulated with anti-CD3/CD28 for 60 hours in Ccr2+/+ and Ccr2−/− mice, 10 days after the first
cycle of CAWS administration. (F) Percentage of Th17 cells (CD4+, IL-17A+) in spleen detected by FACS in Ccr2+/+ and Ccr2−/− mice, after full
cycle of CAWS. (G) Negative correlation between circulating Tregs and Th17 cells in splenocytes cultures. (H) Treg suppression assay showing the
percentage of proliferation of CD4+ responder cells from Ccr2−/− mice cultured with Treg from Ccr2+/+ mice (grey bar) and CD4+ responder cells
from Ccr2+/+ mice cultured with Treg from Ccr2−/− mice (open bar) at different ratios (CD4+ responder : Treg; 1:0, 1:1 and 2:1); analyzed, after a
short cycle of CAWS injections. (I) FACS analysis in blood showing the percentage of Treg in Ccr2+/+, Ccr2−/− and PPGM treated Ccr2+/+ mice for
19 days, after one cycle of CAWS. Each bar represents the mean ± SE from a representative experiment with 6–8 mice per group.









































































































Figure 5 Association of iMo mobilization from bone marrow to periphery with IL-6 increases after CAWS administration.
(A) Representative pathway showing the possible role of iMo releasing IL-6 after CAWS administration activating Th17 cells and inhibiting Treg
cells in Ccr2+/+ mice. (B) Serum levels of IL-6 detected in Ccr2+/+ mice and Ccr2−/− mice, after full cycle of CAWS. (C) IL-6 levels in cell culture
supernatants of splenocytes stimulated with anti-CD3/CD28 for 60 hours in Ccr2+/+ and Ccr2−/− mice, euthanized 10 days after the first cycle of
CAWS administration. (D) FACS showing iMo (CD11b+, Ly6Chi, Ly6Glow) in bone marrow, (E) blood and (F) spleen in Ccr2+/+ and Ccr2−/− mice,
10 days after the first cycle of CAWS or PBS control.
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groups of mice (r=0.62, P=0.02, data not shown).
IMo also called M1 monocytes is a subtype of mono-
cytes thought to be an important cellular source of IL-6
[21,22]. We found that CAWS injection resulted in
mobilization of iMo into the periphery, as indicated by
over a two-fold increase in the proportion of iMo in the
blood and spleen of Ccr2+/+ CAWS-injected compared
to PBS injected mice (Figure 5E and F). The propor-
tion of iMo in the bone marrow (BM) of PBS injected
Ccr2−/−and Ccr2+/+ mice was similar (Figure 5D). How-
ever, CAWS injected Ccr2−/− mice had a lower pro-
portion of iMo in the blood and spleen (Figure 5E-F)than CAWS-injected Ccr2+/+. Together these data
suggest that although Ccr2−/− mice have a similar pro-
portion of iMo in the BM, these cells are not mobilized
into periphery following the challenge with CAWS.
Discussion
As seen in patients with KD, our murine model of cor-
onary vasculitis was characterized mechanistically by the
involvement of T and B cells [23] as well as the
mobilization of iMo [24,25] with an increase of IL-6
levels [9,13]. Moreover, Treg/Th17 cell imbalance was
correlated with a reduction of IL-10 and TGF-β together
with an increase of IL-17 after CAWS administration as
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CCR2, but not CCR5, is protective against CAWS
induced-aortic and coronary vasculitis. Several lines of
evidence support our findings that CCR2 plays a critical
role in the pathogenesis of coronary vasculitis as possibly
seen in KD. First, CCL2 levels, one of the main ligands
for CCR2, are elevated in the serum [26] and urine [27]
of patients with KD in the acute phase of illness; and this
elevation is modulated by treatment [11]. Also, genetic
evidence points towards a role for CCR2 in the patho-
genesis of KD, as suggested by the association between
KD and common genetic variants in the chemokine
receptor gene-cluster CCR3-CCR2-CCR5 [5].
The role of lymphocytes and monocytes/macrophages
has been described as a key factor in the pathogenesis of
KD [9]. Also, in this study we show that T and B cells
played a contributory role in the development of CAWS-
induced vasculitis, as suggested by the decreased incidence
of illness in Rag1−/− mice. However, innate immune
responses play a critical role as 50% of the Rag1−/− mice
still developed a less severe form of the illness. Indeed,
selective absence of B or T cells was not associated with
significant protection, indicating that in this experimental
model the interaction between these two cell types and
the innate immune response provides a high degree of
redundancy. In our study, the development of vasculitis
was likely related to an imbalance between inflammation
and immune regulation, triggered by innate immune
factors such as IL-6. This cytokine has a pivotal function
for dictating whether T cells differentiate into Treg or
Th17 cells [13,28,29]. In the presence of TGF-β and IL-6,
precursors differentiate into Th17 cells, but when only
TGF-β is present will they differentiate into Treg [30].
Thus, IL-6 was likely to inhibit the generation of Treg
and induced the production of IL-17, a potent pro-
inflammatory cytokine. Additionally, levels of mediators
commonly released by Treg, such as IL-10 and TGF-β,
were significantly elevated in Ccr2−/− mice.
In CAWS-injected Ccr2+/+ mice, we found a signifi-
cant depletion of Treg in the periphery that coincided
with an increased proportion of Th17 cells in the
spleen and elevated circulating levels of IL-6. Notably,
Ccr2−/− mice had lower circulating levels of IL-6 com-
pared to Ccr2+/+ mice and interestingly; Ccr2−/− mice
had a higher proportion of circulating Treg after
CAWS. In addition, the important role of Ccr2 to con-
trol Treg function and proliferation in this model was
uncovered by the fact that: i) Ccr2−/− Treg had a
higher suppressor activity on WT responder T cells
and ii) in-vivo blocking of CCR2 increased the propor-
tion of Treg in circulation.
Collectively, these data suggested a mechanistic sce-
nario by which this chemokine receptor was involved in
the innate response to CAWS leading to the rise in IL-6production that favored a Th17 cell response at the
expense of Treg.
Three lines of evidence emphasize the importance of
IL-6 in KD and give credence to the notion that this
mediator may be a determinant of the Treg/Th17 imbal-
ance in the pathogenesis of coronary vasculitis [29].
First, higher levels of IL-6 have been consistently
reported in patients with KD during the acute phase of
illness and serum levels of IL-6 return to normal control
levels following successful treatment and parallels the
duration of the fever [9,31].
Second, comparable to our findings in WT mice
injected with CAWS, which showed a sustained loss of
Treg, the proportion of Treg is lower during acute KD
and tends to normalize after the administration of IVIG
[32]. In addition, has been shown that IVIG induces not
only the expression of CD4+CD25+FoxP3+ cells, but also
the secretion of immunosuppressive TGF-β and IL-10
[33]. Interestingly, the protective phenotype related with
Ccr2−/− mice, was associated with an increase in regula-
tory T cells, TGF-β and IL-10, and a reduction of IL-6
after CAWS administration.
Finally, supporting the role for Th17 responses in KD,
serum IL-17 levels has been shown markedly elevated
in patients with acute KD and positively correlated
with IL-6 levels [34]. Importantly, IL-17 levels gradually
decreased in the subacute phase [13,34].
What was the cellular source of IL-6 in mice injected
with CAWS? In line with our findings in the CAWS-
induced vasculitis, a growing consensus exists that one
of the main pathogenic factors in KD is the activation of
monocytes/macrophages [9,25]. For instance, during the
acute phase, patients with KD have a significant increase
in the absolute numbers of CD14+ monocytes [35], as
well as in the percentage of CD14+CD16- monocytes,
the human correlate of mouse iMo. This increase is
quite specific to KD and severe bacterial infections,
but not to other febrile illness such as pneumonia,
infectious mononucleosis, or anaphylactoid purpura [35].
CD14+CD16- cells also trigger efficient immune responses
[36]. Both, in humans and mice, iMo release high levels
of pro-inflammatory cytokines, including IL-6 [37]. iMo
are directly influenced by CCR2 i.e., cell activation, and
indirectly, i.e., regulation of cell migration [36]. We found
that CAWS injection promoted a CCR2-dependent emi-
gration of iMo from the BM to periphery (i.e., blood,
spleen). Increased availability of iMo in the periphery
creates a readily available cellular source of IL-6. These
findings were not unexpected considering the elegant
work from Serbina et al., and others [36], indicating that
CCR2 is required for the emigration of iMo from the
BM into the periphery.
Some limitations need to be considered. First, no
animal model can recapitulate all the features of KD,
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cell responses in peripheral blood of patients with KD or
in the spleen of CAWS-injected mice prove informative;
and the ongoing T cells dynamics that may be present in
KD at the vascular wall, may not fully parallel our
model, where we see a systemic ongoing immune
activation. Additional experiments are needed to directly
demonstrate the role for IL-6, Treg and Th17 in CAWS-
induced vasculitis via antibody neutralization, genetic
inactivation or cell expansion/depletion.
Conclusion
Collectively, our findings provide novel insights into the
role of CCR2 in the pathogenesis of vasculitis as seen in
KD and other types of vasculitis, and highlighting novel
therapeutic targets specifically for individuals resistant to
first-line treatments.
Methods
Mice, Candida albicans water soluble (CAWS) and
induction of vasculitis
C57BL/6J wild type (WT) and knockout mice (Ccr2−/−,
Ccr5−/−, Nude, Rag1−/− and Igh−/−) received CAWS [39]
by injection (described in Additional file 1). In some
experiments, animals only received the first cycle of
CAWS. All mice were purchased from Jackson Labora-
tories (Bar Harbor, ME) and kept under pathogen-free
conditions. The Institutional Animal Care and Use Com-
mittee of the UTHSCSA approved all protocols. CAWS
was obtained as previously described [39].
Histological evaluation
For this analysis we followed protocols previously
described [40]. Fixed hearts were embedded in OCT and
sectioned. 5–8 μm thick serial sections were collected
every 20 μm, stained with hematoxylin and eosin (H&E)
and examined by light microscopy. Then, for quantita-
tive evaluation of vascular inflammation, we divided the
area of the aortic root and coronary arteries into five
segments that included: right coronary artery (RCA), left
coronary artery (LCA), right coronary cuspid (RCC), left
coronary cuspid (LCC), and non-coronary cuspid
(NCC). Incidence was defined as having one or more
inflamed areas. Also, we measured the area of inflamma-
tion surrounding the aortic root and coronaries as a
proxy for disease severity using the ImageJ software
(NIH, Bethesda).
ELISA and immunostaining
For coronary and aortic analysis, macrophages were
immunostained with the ER-HR3 antibody as previously
described [40]. Area of infiltrating monocytes was quan-
tified using ImageJ software (NIH).Immunolabeling for MPO on tissues was conducted
using a mouse MPO ELISA kit (Hycult Biotechology B.V,
Netherlands). IgG1 and IgG2a antibodies against CAWS
were measured in serum following a previously described
protocol [41], but used CAWS as the antigen (10 μg/ml).
Both, MPO and antibodies against MPO were analyzed
in serum following the manufacturer’s protocols. ELISA
for IL-10 (eBiosciences, San Diego) and TGF-β (R&D
Systems, Minneapolis) were performed according to the
manufacturer’s directions.FACS (fluorescence-activated cell sorting)
Cells from blood, bone marrow (BM), spleen and heart
were used for staining. Leukocytes in the heart were har-
vested by digestion of tissue compromised of the root
of the aorta and portions of the auricular and ventricular
tissue, as previously described [42]. Tregs in whole
blood, spleen and heart were stained with CD4, CD25 and
Foxp3 antibodies following manufacturer’s instructions
(eBiosciences). Antibodies for CD4, CD11b, Ly6C, Ly6G
and I-Ab were purchased from BD Biosciences (San Jose).
Events were acquired in a FACScalibur and data was
analyzed in CellQuest-PRO (BD Biosciences). Antibody
combinations used are presented in (Additional file 6:
Table S1).RNA extraction and real-time PCR (RT-PCR)
Total RNA was extracted from the upper third portion of
the heart, which included the root of the aorta and the cor-
onaries, using the TRIzol reagent (Life Technologies) fol-
lowing manufacturer’s protocol. High capacity cDNA
reverse transcription kit with RNase inhibitor (Applied Bio-
systems, Austin) was used on 500 ng of total RNA. A total
of 125 ng cDNA was used for RT-PCR using Taqman pri-
mer and probe sets for FoxP3-FAM (Mm00475162_m1)
and β-actin-VIC [(Mm00607939_s1) primer limited]
(Applied Biosystems). cDNA samples were run in triplicate
along with normal positive (spleen), negative (pancreas)
and non-template controls. Real-time quantitative PCR was
done with the SsoFast probes supermix (Bio-Rad, Hercules)
in a CFX96 RT-PCR system (Bio-Rad). Threshold cycles
were determined using the CFX Manager software v1.6.
Changes in expression were calculated using the 2-ΔΔCt
method normalized to β-actin expression.Blockage of CCR2 by PPGM
In some experiments, Ccr2 was blocked by oral admi-
nistration of PPGM (Sigma-Aldrich, St. Louis) at a
dose of 8mg/kg/day in the drinking water, for 30 days
starting from the day when the first cycle of CAWS
was injected.
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CD4+CD25+ Treg and CD4+CD25- responder T cells
were isolated from pooled spleens of CAWS-injected
WT and Ccr2−/− mice, using the CD4+CD25+ regulatory
T cell isolation kit with the AutoMACS (Miltenyi Biotec,
Auburn) following manufacturer’s directions. Responder
T cells were labeled with the CFSE cell proliferation kit
(Life Technologies, Carlsbad) according to the kit pro-
tocol. Depleted CD4 cells obtained from the positive
fraction during the first step of the regulatory T cell
isolation, were used as feeder cells after treatment with
50ug/ml mitomycin (Sigma-Aldrich) during 45min,
followed by three washes with RPMI. CD4+CD25-
responder cells (5×104 cells/well initial number) were
stimulated with 1ug/ml of soluble anti-CD3 (BD Bio-
sciences) and syngenic feeder cells (5×104 cells/well).
CD4+CD25+ Treg (5×104 cells/well) were added to the
corresponding wells to the above cultures, and cells were
incubated at 37o for 72hrs. Each ratio of responder:Treg
cells was run in triplicate. After 72hrs, cells were col-
lected, washed and analyzed by FACS as described
above. Proliferation gates were determined from wells
where responder T cells lacked Treg, and from wells
where responder T cells were cultured alone without
stimulation (CD3 and feeder cells).Immune cell transfers
Isolation of untouched T and B cells from spleens
derived from Ccr2+/+ or Ccr2−/− mice were done using
the Pan T cell isolation kit and the B cell isolation kit
from Miltenyi Biotec. Cell purifications were performed
with the AutoMACS (Miltenyi Biotec) according to the
manufacturer’s directions. Levels of purity post-
purification were determined by FACS and found to be
above 90% for each cell population. Recipient mice
received 1×106 B and/or T cells via tail vein injection.
To verify the reconstitution of T and B cells in each
mouse, we stained the cells from the blood and spleen
with CD4 and CD19 antibodies at the time of the sacrifice
for FACS analysis. Recipient mice had higher percentages
of T and/or B cells compared to PBS-treated mice; however
no differences in the degree of reconstitution occurred
between the recipients of Ccr2+/+ or Ccr2−/− cells.Statistical analysis and data modeling
Data represent the mean ± SD. Groups were analyzed
with Stata (StataCorp) or SPSS statistical software.
According to the number of groups and the distribution
(normally distributed or not), non-paired t test, one-way
ANOVA, Kruskal-Wallis, Mann–Whitney, or Fisher’s
exact tests were performed. Statistical significance was
accepted at p< 0.05.Additional files
Additional file 1: Figure S1. Protocol for coronary/aortic inflammation
in mice using CAWS. A full cycle of CAWS included two rounds of intra-
peritoneal (I.P.) injections (1 mg/mouse/day for five consecutive days)
administered four weeks apart as previously described47-51. Early
experiments were conducted with a dose of 4 mg instead of 1 mg of
CAWS per day. Results derived from either dose had identical disease
incidence and severity. In some experiments, mice were sacrificed 10
days after the first five days of CAWS injections (cycle one). At this time
point we were unable to identify ongoing inflammation in the coronary
or aortic walls (data not shown). We identified inflammation clearly and
consistently in 100% of mice 30 days after the completion of the first
cycle.
Additional file 2: Figure S2. Coronary and aortic analysis of
macrophages. Coronary and aortic macrophages were immunostained
with the ER-HR3 antibody in Ccr2+/+ and Ccr2−/− mice including isotype
control.
Additional file 3: Figure S3. Serum levels of Myeloperoxidase (MPO).
MPO levels were detected by ELISA after full cycle of CAWS in Ccr2+/+
and Ccr2−/− mice.
Additional file 4: Figure S4. Antibody against MPO (anti-MPO), IgG1
and IgG2a levels Ccr2+/+ and Ccr2−/− mice after full cycles of CAWS. A.
Serum antibodies against MPO detected by ELISA in Ccr2+/+ and Ccr2
−/− mice after two cycles of CAWS, including PBS control (values
expressed as optical density). B-C. Serum levels of anti-IgG1 and anti-
IgG2a, in Ccr2+/+ and Ccr2−/− mice after two cycles of CAWS.
Additional file 5: Figure S5. Th1 and Th2 response in spleen of Ccr2+/+
and Ccr2−/− mice. Percentage of IFNγ (Th1) and IL-4 (Th2) in splenocytes
after full cycle of CAWS in Ccr2+/+ and Ccr2−/− mice. Each bar represents
the mean ± SE from a representative experiment with 6–8 mice per
group.
Additional file 6: Table S1. Flow cytometric markers used to identify
specific cell type.
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